 Robert Weinstein
Concepts (858)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 145 | 2021 | 293 | 17.440 |
Why?
| | Infection Control | 77 | 2021 | 171 | 9.320 |
Why?
| | Staphylococcal Infections | 44 | 2021 | 176 | 8.440 |
Why?
| | Anti-Bacterial Agents | 79 | 2021 | 412 | 8.350 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 31 | 2021 | 110 | 7.570 |
Why?
| | Intensive Care Units | 61 | 2021 | 316 | 5.220 |
Why?
| | Bacteremia | 35 | 2019 | 122 | 5.160 |
Why?
| | Drug Resistance, Bacterial | 18 | 2021 | 55 | 3.390 |
Why?
| | Enterococcus | 26 | 2014 | 62 | 3.210 |
Why?
| | Humans | 312 | 2022 | 31481 | 3.140 |
Why?
| | Drug Resistance, Microbial | 44 | 2015 | 96 | 3.110 |
Why?
| | Klebsiella pneumoniae | 19 | 2021 | 60 | 3.090 |
Why?
| | Community-Acquired Infections | 20 | 2021 | 77 | 2.930 |
Why?
| | Klebsiella Infections | 17 | 2020 | 55 | 2.800 |
Why?
| | Enterobacteriaceae Infections | 22 | 2021 | 48 | 2.730 |
Why?
| | Chlorhexidine | 19 | 2019 | 54 | 2.720 |
Why?
| | Gram-Positive Bacterial Infections | 22 | 2014 | 63 | 2.660 |
Why?
| | Disease Outbreaks | 29 | 2017 | 87 | 2.500 |
Why?
| | Catheterization, Central Venous | 17 | 2014 | 44 | 2.490 |
Why?
| | Chicago | 48 | 2021 | 955 | 2.310 |
Why?
| | Hospitals | 34 | 2020 | 142 | 2.280 |
Why?
| | Carrier State | 20 | 2019 | 52 | 2.250 |
Why?
| | Anti-Infective Agents | 13 | 2016 | 59 | 2.230 |
Why?
| | Surgical Wound Infection | 13 | 2019 | 106 | 2.190 |
Why?
| | beta-Lactamases | 18 | 2021 | 80 | 2.170 |
Why?
| | Bacterial Proteins | 17 | 2021 | 90 | 2.160 |
Why?
| | Carbapenems | 10 | 2019 | 32 | 2.160 |
Why?
| | Population Surveillance | 15 | 2018 | 127 | 2.120 |
Why?
| | AIDS-Related Opportunistic Infections | 19 | 2010 | 49 | 2.030 |
Why?
| | Anti-Infective Agents, Local | 15 | 2019 | 50 | 2.010 |
Why?
| | Drug Resistance, Multiple, Bacterial | 17 | 2020 | 49 | 1.920 |
Why?
| | Hand Disinfection | 14 | 2019 | 24 | 1.870 |
Why?
| | Enterobacteriaceae | 17 | 2020 | 39 | 1.850 |
Why?
| | Methicillin Resistance | 10 | 2012 | 33 | 1.800 |
Why?
| | Vancomycin | 15 | 2012 | 56 | 1.780 |
Why?
| | Vancomycin Resistance | 14 | 2014 | 31 | 1.770 |
Why?
| | Baths | 10 | 2019 | 26 | 1.770 |
Why?
| | Male | 127 | 2022 | 17583 | 1.750 |
Why?
| | Staphylococcus aureus | 16 | 2021 | 87 | 1.730 |
Why?
| | Hospitalization | 20 | 2021 | 359 | 1.730 |
Why?
| | Pneumonia, Pneumocystis | 19 | 2010 | 33 | 1.700 |
Why?
| | Bacterial Infections | 12 | 2021 | 71 | 1.660 |
Why?
| | Practice Guidelines as Topic | 13 | 2018 | 389 | 1.660 |
Why?
| | Female | 124 | 2022 | 18253 | 1.650 |
Why?
| | HIV Infections | 14 | 2013 | 951 | 1.650 |
Why?
| | Adult | 82 | 2022 | 9779 | 1.420 |
Why?
| | Middle Aged | 94 | 2022 | 11209 | 1.390 |
Why?
| | Probiotics | 2 | 2018 | 18 | 1.340 |
Why?
| | Equipment Contamination | 12 | 2019 | 27 | 1.340 |
Why?
| | Gloves, Protective | 7 | 2019 | 15 | 1.330 |
Why?
| | Medical Staff, Hospital | 3 | 2017 | 21 | 1.310 |
Why?
| | Risk Factors | 39 | 2021 | 2664 | 1.300 |
Why?
| | Internal Medicine | 3 | 2017 | 34 | 1.240 |
Why?
| | Communicable Diseases | 4 | 2016 | 18 | 1.240 |
Why?
| | Skin | 12 | 2018 | 136 | 1.230 |
Why?
| | Clostridium Infections | 4 | 2018 | 13 | 1.230 |
Why?
| | Gram-Negative Bacterial Infections | 9 | 2015 | 26 | 1.170 |
Why?
| | Prevalence | 19 | 2021 | 544 | 1.170 |
Why?
| | Guideline Adherence | 8 | 2014 | 77 | 1.140 |
Why?
| | Illinois | 13 | 2021 | 266 | 1.080 |
Why?
| | Aged | 64 | 2022 | 10295 | 1.050 |
Why?
| | Genomics | 6 | 2021 | 46 | 1.040 |
Why?
| | Sepsis | 10 | 2014 | 157 | 1.040 |
Why?
| | Microbial Sensitivity Tests | 28 | 2021 | 117 | 1.030 |
Why?
| | Antibiotic Prophylaxis | 5 | 2016 | 37 | 1.000 |
Why?
| | Drug Utilization | 8 | 2009 | 27 | 0.990 |
Why?
| | Drug Utilization Review | 3 | 2009 | 7 | 0.950 |
Why?
| | Catheters, Indwelling | 7 | 2006 | 30 | 0.950 |
Why?
| | Molecular Typing | 4 | 2021 | 9 | 0.920 |
Why?
| | Catheterization | 8 | 2007 | 62 | 0.920 |
Why?
| | Prisons | 3 | 2013 | 13 | 0.920 |
Why?
| | Q Fever | 2 | 2016 | 5 | 0.900 |
Why?
| | United States | 39 | 2019 | 2539 | 0.900 |
Why?
| | Mass Screening | 4 | 2015 | 199 | 0.900 |
Why?
| | Physicians | 6 | 2016 | 120 | 0.880 |
Why?
| | Personnel, Hospital | 7 | 2009 | 18 | 0.860 |
Why?
| | Hand | 6 | 2008 | 49 | 0.860 |
Why?
| | Tuberculosis, Pulmonary | 5 | 2009 | 8 | 0.850 |
Why?
| | Influenza, Human | 1 | 2021 | 52 | 0.840 |
Why?
| | Protective Clothing | 3 | 2019 | 10 | 0.840 |
Why?
| | Cost-Benefit Analysis | 4 | 2015 | 153 | 0.810 |
Why?
| | Long-Term Care | 11 | 2019 | 58 | 0.810 |
Why?
| | Ventilation | 2 | 2017 | 4 | 0.810 |
Why?
| | Catheter-Related Infections | 6 | 2014 | 26 | 0.810 |
Why?
| | DNA, Bacterial | 9 | 2019 | 54 | 0.810 |
Why?
| | Health Care Costs | 3 | 2010 | 81 | 0.810 |
Why?
| | Public Health | 3 | 2019 | 66 | 0.800 |
Why?
| | Evolution, Molecular | 2 | 2017 | 8 | 0.790 |
Why?
| | Models, Economic | 3 | 2010 | 10 | 0.780 |
Why?
| | Patient Isolation | 8 | 2010 | 24 | 0.780 |
Why?
| | Pseudomonas Infections | 14 | 2017 | 63 | 0.780 |
Why?
| | Quality of Health Care | 7 | 2005 | 141 | 0.770 |
Why?
| | Smoke | 1 | 2018 | 4 | 0.770 |
Why?
| | Genotype | 4 | 2019 | 423 | 0.760 |
Why?
| | Hospitals, Teaching | 10 | 2018 | 37 | 0.750 |
Why?
| | Conflict of Interest | 1 | 2018 | 19 | 0.750 |
Why?
| | Adolescent | 27 | 2022 | 2667 | 0.740 |
Why?
| | Catheterization, Peripheral | 4 | 2002 | 18 | 0.720 |
Why?
| | Retrospective Studies | 29 | 2021 | 3591 | 0.720 |
Why?
| | Case-Control Studies | 13 | 2022 | 687 | 0.710 |
Why?
| | Gram-Negative Bacteria | 12 | 2013 | 37 | 0.710 |
Why?
| | Infectious Disease Transmission, Professional-to-Patient | 3 | 2008 | 6 | 0.710 |
Why?
| | Primary Prevention | 1 | 2018 | 53 | 0.700 |
Why?
| | Genome, Bacterial | 5 | 2017 | 13 | 0.690 |
Why?
| | Medical Audit | 1 | 2017 | 8 | 0.690 |
Why?
| | Inappropriate Prescribing | 1 | 2017 | 5 | 0.690 |
Why?
| | Acquired Immunodeficiency Syndrome | 7 | 2006 | 100 | 0.680 |
Why?
| | Hospital Costs | 3 | 2014 | 73 | 0.680 |
Why?
| | Hospitals, Public | 11 | 2015 | 31 | 0.680 |
Why?
| | Nursing Homes | 7 | 2020 | 42 | 0.680 |
Why?
| | Bacterial Typing Techniques | 3 | 2016 | 12 | 0.680 |
Why?
| | Acinetobacter Infections | 3 | 2019 | 6 | 0.670 |
Why?
| | Patient Care | 3 | 2013 | 35 | 0.660 |
Why?
| | Nasal Cavity | 4 | 2014 | 36 | 0.650 |
Why?
| | Cesarean Section | 1 | 2016 | 33 | 0.650 |
Why?
| | Registries | 3 | 2022 | 214 | 0.640 |
Why?
| | Drug Resistance, Multiple | 6 | 2012 | 12 | 0.630 |
Why?
| | Acinetobacter baumannii | 2 | 2019 | 5 | 0.630 |
Why?
| | Lactobacillus | 1 | 2016 | 20 | 0.630 |
Why?
| | Doxycycline | 1 | 2016 | 23 | 0.630 |
Why?
| | State Medicine | 1 | 2015 | 3 | 0.620 |
Why?
| | Health Information Exchange | 1 | 2015 | 4 | 0.620 |
Why?
| | Critical Care | 8 | 2018 | 234 | 0.620 |
Why?
| | Aerosols | 3 | 2013 | 23 | 0.620 |
Why?
| | Length of Stay | 6 | 2014 | 377 | 0.610 |
Why?
| | Health Personnel | 4 | 2021 | 108 | 0.600 |
Why?
| | Health Resources | 2 | 2010 | 28 | 0.590 |
Why?
| | Anesthesia | 1 | 2015 | 29 | 0.580 |
Why?
| | Anesthesiology | 1 | 2015 | 28 | 0.570 |
Why?
| | Pharynx | 1 | 2014 | 14 | 0.560 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 12 | 2015 | 39 | 0.550 |
Why?
| | Medical Records Systems, Computerized | 3 | 2009 | 12 | 0.550 |
Why?
| | Urban Population | 3 | 2021 | 161 | 0.550 |
Why?
| | Specimen Handling | 5 | 2017 | 50 | 0.550 |
Why?
| | Platelet-Rich Plasma | 2 | 2016 | 67 | 0.550 |
Why?
| | Sequence Analysis, DNA | 5 | 2017 | 81 | 0.540 |
Why?
| | Bacteria | 7 | 2017 | 74 | 0.540 |
Why?
| | Prospective Studies | 25 | 2019 | 1934 | 0.540 |
Why?
| | Pneumococcal Vaccines | 2 | 2004 | 5 | 0.530 |
Why?
| | Time Factors | 20 | 2022 | 1902 | 0.520 |
Why?
| | Program Evaluation | 3 | 2009 | 153 | 0.520 |
Why?
| | Air Microbiology | 1 | 2013 | 3 | 0.510 |
Why?
| | Fungi | 1 | 2013 | 6 | 0.510 |
Why?
| | Disease Transmission, Infectious | 5 | 2019 | 22 | 0.490 |
Why?
| | Child | 15 | 2021 | 1572 | 0.490 |
Why?
| | Disease Notification | 2 | 2018 | 4 | 0.490 |
Why?
| | Students, Medical | 1 | 2012 | 46 | 0.490 |
Why?
| | Molecular Epidemiology | 9 | 2021 | 29 | 0.480 |
Why?
| | Alveolar Bone Loss | 2 | 2013 | 3 | 0.480 |
Why?
| | Mupirocin | 5 | 2019 | 15 | 0.480 |
Why?
| | Staphylococcal Skin Infections | 3 | 2011 | 14 | 0.480 |
Why?
| | Cephalosporins | 9 | 2019 | 18 | 0.470 |
Why?
| | Costs and Cost Analysis | 4 | 2010 | 39 | 0.470 |
Why?
| | Emergency Medical Services | 2 | 2014 | 40 | 0.470 |
Why?
| | Phenotype | 8 | 2021 | 379 | 0.470 |
Why?
| | Pharmacy Service, Hospital | 4 | 2006 | 10 | 0.460 |
Why?
| | Tertiary Care Centers | 4 | 2019 | 82 | 0.460 |
Why?
| | Multivariate Analysis | 12 | 2013 | 390 | 0.450 |
Why?
| | Streptococcal Infections | 2 | 2002 | 17 | 0.450 |
Why?
| | Communicable Disease Control | 5 | 2006 | 12 | 0.450 |
Why?
| | Water Microbiology | 3 | 2020 | 12 | 0.450 |
Why?
| | Gingival Recession | 1 | 2010 | 1 | 0.450 |
Why?
| | Furcation Defects | 1 | 2010 | 1 | 0.450 |
Why?
| | Evidence-Based Dentistry | 1 | 2010 | 1 | 0.450 |
Why?
| | Guidelines as Topic | 5 | 2009 | 79 | 0.440 |
Why?
| | Antiretroviral Therapy, Highly Active | 4 | 2010 | 151 | 0.440 |
Why?
| | Fluoroquinolones | 3 | 2019 | 25 | 0.430 |
Why?
| | Disinfectants | 3 | 2014 | 9 | 0.430 |
Why?
| | Hospital Mortality | 8 | 2010 | 192 | 0.430 |
Why?
| | Medical Records | 4 | 2005 | 40 | 0.420 |
Why?
| | HIV Seropositivity | 2 | 2004 | 98 | 0.420 |
Why?
| | Medicaid | 3 | 2006 | 43 | 0.420 |
Why?
| | Alcohols | 5 | 2007 | 7 | 0.420 |
Why?
| | Housekeeping, Hospital | 2 | 2008 | 5 | 0.420 |
Why?
| | Infant | 9 | 2021 | 642 | 0.420 |
Why?
| | Tuberculosis, Multidrug-Resistant | 2 | 2000 | 2 | 0.410 |
Why?
| | Hospital Information Systems | 2 | 2014 | 5 | 0.410 |
Why?
| | Algorithms | 6 | 2014 | 412 | 0.410 |
Why?
| | DNA Fingerprinting | 3 | 2016 | 6 | 0.400 |
Why?
| | Pharmacists | 2 | 2006 | 16 | 0.400 |
Why?
| | Pseudomonas aeruginosa | 14 | 2017 | 85 | 0.400 |
Why?
| | Hospitals, Urban | 8 | 2015 | 37 | 0.390 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2009 | 11 | 0.390 |
Why?
| | Respiration, Artificial | 7 | 2015 | 116 | 0.390 |
Why?
| | Soft Tissue Infections | 3 | 2011 | 25 | 0.390 |
Why?
| | Occupational Diseases | 1 | 2009 | 26 | 0.390 |
Why?
| | Health Knowledge, Attitudes, Practice | 4 | 2008 | 230 | 0.380 |
Why?
| | Pandemics | 2 | 2021 | 203 | 0.380 |
Why?
| | Child, Preschool | 8 | 2021 | 786 | 0.380 |
Why?
| | Escherichia coli | 7 | 2012 | 66 | 0.380 |
Why?
| | Rectum | 7 | 2017 | 72 | 0.380 |
Why?
| | Ceftazidime | 7 | 2001 | 13 | 0.370 |
Why?
| | Ambulatory Care | 2 | 2006 | 90 | 0.370 |
Why?
| | Feces | 4 | 2017 | 82 | 0.370 |
Why?
| | Acinetobacter | 1 | 2008 | 2 | 0.370 |
Why?
| | Pneumonia, Ventilator-Associated | 4 | 2015 | 18 | 0.370 |
Why?
| | Decontamination | 4 | 2008 | 10 | 0.360 |
Why?
| | Disinfection | 3 | 2019 | 13 | 0.360 |
Why?
| | Escherichia coli Infections | 6 | 2014 | 32 | 0.360 |
Why?
| | Drug Contamination | 3 | 2001 | 7 | 0.350 |
Why?
| | Delivery of Health Care | 2 | 2009 | 130 | 0.350 |
Why?
| | Skin Care | 4 | 2018 | 16 | 0.350 |
Why?
| | Public Housing | 1 | 2007 | 5 | 0.350 |
Why?
| | Developing Countries | 2 | 2005 | 22 | 0.340 |
Why?
| | Penicillins | 3 | 2002 | 13 | 0.340 |
Why?
| | Amikacin | 4 | 1998 | 7 | 0.340 |
Why?
| | Infant, Newborn | 9 | 2021 | 754 | 0.340 |
Why?
| | Ciprofloxacin | 5 | 2003 | 28 | 0.340 |
Why?
| | Serratia Infections | 2 | 2010 | 10 | 0.340 |
Why?
| | Pneumonia | 5 | 1998 | 74 | 0.340 |
Why?
| | Hospital Administration | 3 | 2021 | 25 | 0.340 |
Why?
| | Education, Medical | 1 | 2007 | 45 | 0.340 |
Why?
| | Dental Implantation, Endosseous | 2 | 2017 | 2 | 0.340 |
Why?
| | Incidence | 11 | 2013 | 829 | 0.330 |
Why?
| | Cohort Studies | 13 | 2022 | 2014 | 0.330 |
Why?
| | Hospital Units | 2 | 2004 | 12 | 0.330 |
Why?
| | Enterobacter | 8 | 2001 | 8 | 0.330 |
Why?
| | Bacteriological Techniques | 6 | 2017 | 20 | 0.330 |
Why?
| | Young Adult | 8 | 2022 | 2277 | 0.320 |
Why?
| | Cost of Illness | 1 | 2006 | 65 | 0.320 |
Why?
| | Rifampin | 1 | 2006 | 6 | 0.320 |
Why?
| | Silver | 1 | 2006 | 4 | 0.320 |
Why?
| | Minocycline | 1 | 2006 | 8 | 0.320 |
Why?
| | Referral and Consultation | 4 | 2007 | 99 | 0.320 |
Why?
| | Drug Therapy, Combination | 4 | 2011 | 265 | 0.310 |
Why?
| | Enterococcus faecium | 4 | 2001 | 16 | 0.310 |
Why?
| | Problem-Based Learning | 1 | 2006 | 11 | 0.310 |
Why?
| | Nose | 3 | 2013 | 35 | 0.310 |
Why?
| | Information Services | 1 | 2005 | 4 | 0.310 |
Why?
| | Daptomycin | 1 | 2005 | 17 | 0.300 |
Why?
| | Dental Implants | 2 | 2017 | 8 | 0.300 |
Why?
| | Research | 1 | 2006 | 64 | 0.300 |
Why?
| | Urinary Tract Infections | 5 | 2015 | 34 | 0.300 |
Why?
| | Pneumonia, Bacterial | 3 | 2017 | 15 | 0.300 |
Why?
| | Education, Medical, Continuing | 1 | 2006 | 47 | 0.300 |
Why?
| | Nursing Records | 1 | 2005 | 10 | 0.300 |
Why?
| | Culture Media | 5 | 2017 | 44 | 0.300 |
Why?
| | Gram-Negative Aerobic Bacteria | 3 | 2005 | 4 | 0.290 |
Why?
| | Community Health Centers | 1 | 2005 | 14 | 0.290 |
Why?
| | Subacute Care | 2 | 2021 | 5 | 0.290 |
Why?
| | Streptococcus pneumoniae | 2 | 2002 | 7 | 0.290 |
Why?
| | Plasmids | 6 | 2019 | 52 | 0.290 |
Why?
| | Dental Plaque | 1 | 2004 | 1 | 0.290 |
Why?
| | Quality Indicators, Health Care | 1 | 2005 | 43 | 0.290 |
Why?
| | Aged, 80 and over | 18 | 2022 | 5234 | 0.290 |
Why?
| | Mouthwashes | 1 | 2004 | 6 | 0.290 |
Why?
| | Communicable Diseases, Emerging | 1 | 2004 | 2 | 0.280 |
Why?
| | Bacterial Load | 3 | 2013 | 13 | 0.280 |
Why?
| | Point-of-Care Systems | 1 | 2004 | 29 | 0.280 |
Why?
| | Masks | 2 | 2021 | 4 | 0.280 |
Why?
| | Attitude of Health Personnel | 4 | 2014 | 181 | 0.270 |
Why?
| | Natural Language Processing | 1 | 2003 | 8 | 0.270 |
Why?
| | Diarrhea | 2 | 2008 | 50 | 0.270 |
Why?
| | Coxiella burnetii | 1 | 2003 | 4 | 0.270 |
Why?
| | Bioterrorism | 1 | 2003 | 6 | 0.270 |
Why?
| | Vaccination | 1 | 2004 | 43 | 0.270 |
Why?
| | Hospitals, University | 3 | 2015 | 46 | 0.270 |
Why?
| | Radiology | 1 | 2003 | 22 | 0.270 |
Why?
| | Colony Count, Microbial | 6 | 2015 | 24 | 0.270 |
Why?
| | Radiography, Thoracic | 1 | 2003 | 39 | 0.270 |
Why?
| | Vancomycin-Resistant Enterococci | 2 | 2020 | 5 | 0.270 |
Why?
| | Health Behavior | 2 | 2021 | 177 | 0.260 |
Why?
| | Unnecessary Procedures | 1 | 2004 | 30 | 0.260 |
Why?
| | Phylogeny | 3 | 2021 | 67 | 0.260 |
Why?
| | Ventilators, Mechanical | 2 | 2000 | 20 | 0.260 |
Why?
| | Databases as Topic | 1 | 2003 | 22 | 0.260 |
Why?
| | Digestive System Diseases | 1 | 2003 | 6 | 0.260 |
Why?
| | Computers | 1 | 2003 | 26 | 0.260 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2017 | 52 | 0.260 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2003 | 84 | 0.260 |
Why?
| | Enterocolitis, Pseudomembranous | 2 | 2002 | 16 | 0.260 |
Why?
| | Critical Illness | 4 | 2018 | 125 | 0.250 |
Why?
| | Nursing Staff, Hospital | 1 | 2003 | 71 | 0.250 |
Why?
| | Gels | 1 | 2002 | 11 | 0.250 |
Why?
| | Hospitals, Private | 1 | 2002 | 2 | 0.250 |
Why?
| | Hospitals, County | 1 | 2002 | 4 | 0.250 |
Why?
| | Patient Care Team | 3 | 2010 | 153 | 0.250 |
Why?
| | Infusions, Intravenous | 2 | 2005 | 89 | 0.250 |
Why?
| | Water Supply | 1 | 2002 | 4 | 0.250 |
Why?
| | African Americans | 4 | 2021 | 818 | 0.250 |
Why?
| | Treatment Outcome | 13 | 2018 | 3910 | 0.250 |
Why?
| | Gentamicins | 5 | 1995 | 15 | 0.250 |
Why?
| | Renal Insufficiency | 1 | 2002 | 22 | 0.250 |
Why?
| | Medication Systems | 1 | 2002 | 2 | 0.240 |
Why?
| | Penicillin Resistance | 1 | 2002 | 1 | 0.240 |
Why?
| | Quinine | 1 | 2002 | 1 | 0.240 |
Why?
| | Cross-Over Studies | 3 | 2013 | 82 | 0.240 |
Why?
| | Patient Transfer | 2 | 2012 | 24 | 0.240 |
Why?
| | Intestines | 3 | 2007 | 114 | 0.240 |
Why?
| | Legislation, Hospital | 1 | 2001 | 1 | 0.240 |
Why?
| | Cooperative Behavior | 2 | 2016 | 86 | 0.230 |
Why?
| | Sucralfate | 2 | 1991 | 3 | 0.230 |
Why?
| | Peer Review, Health Care | 1 | 2001 | 1 | 0.230 |
Why?
| | Selection Bias | 1 | 2001 | 9 | 0.230 |
Why?
| | Professional Staff Committees | 1 | 2001 | 9 | 0.230 |
Why?
| | APACHE | 3 | 2009 | 32 | 0.230 |
Why?
| | Quality Improvement | 3 | 2018 | 173 | 0.220 |
Why?
| | Spinal Puncture | 2 | 2000 | 23 | 0.220 |
Why?
| | Gammaproteobacteria | 1 | 2021 | 3 | 0.220 |
Why?
| | Homosexuality, Male | 2 | 2020 | 25 | 0.220 |
Why?
| | Reproducibility of Results | 5 | 2014 | 886 | 0.220 |
Why?
| | Environmental Microbiology | 2 | 2017 | 4 | 0.220 |
Why?
| | Emergency Service, Hospital | 3 | 2012 | 180 | 0.220 |
Why?
| | Skilled Nursing Facilities | 3 | 2015 | 19 | 0.220 |
Why?
| | Meningitis, Bacterial | 1 | 2000 | 9 | 0.220 |
Why?
| | Erythropoietin | 1 | 2001 | 50 | 0.220 |
Why?
| | Clinical Protocols | 1 | 2021 | 75 | 0.220 |
Why?
| | Iatrogenic Disease | 1 | 2000 | 26 | 0.210 |
Why?
| | Enterococcus faecalis | 2 | 1997 | 8 | 0.210 |
Why?
| | Neutropenia | 3 | 2008 | 26 | 0.210 |
Why?
| | Staphylococcus | 5 | 1993 | 11 | 0.210 |
Why?
| | Fresh Water | 1 | 2020 | 5 | 0.210 |
Why?
| | Health Status Disparities | 1 | 2021 | 70 | 0.210 |
Why?
| | Klebsiella | 2 | 1999 | 2 | 0.210 |
Why?
| | Palliative Care | 1 | 2022 | 146 | 0.210 |
Why?
| | Digestive System | 3 | 2000 | 19 | 0.210 |
Why?
| | Epidemiology | 2 | 1998 | 5 | 0.200 |
Why?
| | Lung | 2 | 1998 | 171 | 0.200 |
Why?
| | Cross-Sectional Studies | 6 | 2021 | 986 | 0.200 |
Why?
| | Mycobacterium tuberculosis | 2 | 1998 | 17 | 0.200 |
Why?
| | Animals | 12 | 2017 | 5312 | 0.200 |
Why?
| | Cardiac Surgical Procedures | 6 | 1988 | 98 | 0.200 |
Why?
| | Proportional Hazards Models | 4 | 2019 | 390 | 0.190 |
Why?
| | Tobramycin | 2 | 1998 | 11 | 0.190 |
Why?
| | Hospital Bed Capacity, 500 and over | 3 | 2012 | 9 | 0.190 |
Why?
| | Drug Costs | 2 | 2010 | 18 | 0.190 |
Why?
| | Risk Assessment | 4 | 2015 | 806 | 0.190 |
Why?
| | Medical Errors | 1 | 2019 | 31 | 0.190 |
Why?
| | Species Specificity | 2 | 2016 | 78 | 0.190 |
Why?
| | Hygiene | 4 | 2019 | 13 | 0.190 |
Why?
| | Workload | 2 | 2012 | 41 | 0.190 |
Why?
| | Risk | 7 | 2003 | 228 | 0.190 |
Why?
| | Genetic Variation | 3 | 2014 | 113 | 0.180 |
Why?
| | Consensus Development Conferences as Topic | 1 | 1998 | 6 | 0.180 |
Why?
| | Specialties, Nursing | 1 | 1998 | 11 | 0.180 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 16 | 0.180 |
Why?
| | Sensitivity and Specificity | 5 | 2018 | 580 | 0.180 |
Why?
| | Tuberculosis | 2 | 1997 | 24 | 0.180 |
Why?
| | HIV-1 | 4 | 1995 | 446 | 0.170 |
Why?
| | American Hospital Association | 2 | 1994 | 2 | 0.170 |
Why?
| | Fomites | 2 | 2008 | 4 | 0.170 |
Why?
| | Decision Making, Computer-Assisted | 1 | 2017 | 6 | 0.170 |
Why?
| | Logistic Models | 7 | 2019 | 479 | 0.170 |
Why?
| | Travel | 2 | 2014 | 15 | 0.170 |
Why?
| | Preservation, Biological | 1 | 1997 | 5 | 0.170 |
Why?
| | Feedback | 1 | 2017 | 26 | 0.170 |
Why?
| | Transfusion Reaction | 2 | 1995 | 9 | 0.170 |
Why?
| | Environment, Controlled | 1 | 2017 | 1 | 0.170 |
Why?
| | Greece | 1 | 2017 | 2 | 0.170 |
Why?
| | Latin America | 1 | 2017 | 7 | 0.170 |
Why?
| | Israel | 1 | 2017 | 19 | 0.170 |
Why?
| | Microbiology | 1 | 2016 | 2 | 0.170 |
Why?
| | Regression Analysis | 6 | 2019 | 319 | 0.170 |
Why?
| | Bacterial Translocation | 4 | 2001 | 35 | 0.170 |
Why?
| | Prognosis | 7 | 2022 | 1028 | 0.170 |
Why?
| | Endocarditis, Bacterial | 2 | 1996 | 17 | 0.170 |
Why?
| | Substance Abuse, Intravenous | 2 | 1996 | 12 | 0.170 |
Why?
| | Respiratory Tract Infections | 3 | 1996 | 25 | 0.170 |
Why?
| | Osseointegration | 1 | 2017 | 72 | 0.170 |
Why?
| | Jurisprudence | 1 | 1996 | 3 | 0.160 |
Why?
| | Gloves, Surgical | 1 | 1996 | 7 | 0.160 |
Why?
| | Health Care Surveys | 6 | 2014 | 77 | 0.160 |
Why?
| | Professional Role | 1 | 2016 | 26 | 0.160 |
Why?
| | Sinus Floor Augmentation | 1 | 2016 | 1 | 0.160 |
Why?
| | Gram-Positive Bacteria | 3 | 2012 | 17 | 0.160 |
Why?
| | Maxilla | 1 | 2016 | 2 | 0.160 |
Why?
| | Quinolones | 1 | 1996 | 23 | 0.160 |
Why?
| | beta-Lactam Resistance | 3 | 2017 | 16 | 0.160 |
Why?
| | Program Development | 1 | 2016 | 76 | 0.160 |
Why?
| | Hydroxyapatites | 1 | 2016 | 9 | 0.160 |
Why?
| | RNA, Bacterial | 1 | 2016 | 3 | 0.160 |
Why?
| | Nontuberculous Mycobacteria | 2 | 2015 | 5 | 0.160 |
Why?
| | Pregnancy | 2 | 2016 | 457 | 0.160 |
Why?
| | Mycobacterium Infections, Nontuberculous | 2 | 2015 | 8 | 0.160 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2016 | 47 | 0.160 |
Why?
| | Pilot Projects | 4 | 2020 | 455 | 0.160 |
Why?
| | Physician-Patient Relations | 1 | 1996 | 47 | 0.160 |
Why?
| | Equipment and Supplies | 2 | 2010 | 16 | 0.160 |
Why?
| | Histiocytosis, Non-Langerhans-Cell | 1 | 1995 | 3 | 0.160 |
Why?
| | Bone Matrix | 1 | 2016 | 33 | 0.160 |
Why?
| | Histoplasmosis | 1 | 1995 | 9 | 0.160 |
Why?
| | Titanium | 1 | 2017 | 204 | 0.160 |
Why?
| | Zidovudine | 2 | 1992 | 39 | 0.160 |
Why?
| | HIV Seronegativity | 1 | 1996 | 44 | 0.150 |
Why?
| | Data Collection | 3 | 2006 | 120 | 0.150 |
Why?
| | Candidiasis | 1 | 2015 | 23 | 0.150 |
Why?
| | Poisson Distribution | 3 | 2015 | 26 | 0.150 |
Why?
| | Thienamycins | 4 | 1998 | 7 | 0.150 |
Why?
| | Imipenem | 4 | 1998 | 7 | 0.150 |
Why?
| | Insurance, Health | 3 | 2003 | 27 | 0.150 |
Why?
| | Survival Analysis | 3 | 2008 | 379 | 0.150 |
Why?
| | Nystatin | 1 | 1995 | 3 | 0.150 |
Why?
| | Colistin | 1 | 1995 | 5 | 0.150 |
Why?
| | Residence Characteristics | 2 | 2014 | 226 | 0.150 |
Why?
| | Cluster Analysis | 5 | 2015 | 55 | 0.150 |
Why?
| | Interferon-alpha | 2 | 1992 | 71 | 0.150 |
Why?
| | Bacteriuria | 2 | 2015 | 6 | 0.150 |
Why?
| | Tuberculin Test | 2 | 2009 | 14 | 0.150 |
Why?
| | Communication | 1 | 1996 | 129 | 0.150 |
Why?
| | Terminally Ill | 1 | 2014 | 5 | 0.150 |
Why?
| | Evidence-Based Medicine | 4 | 2008 | 239 | 0.150 |
Why?
| | Diagnosis, Differential | 2 | 2016 | 467 | 0.150 |
Why?
| | Databases, Factual | 3 | 2019 | 391 | 0.140 |
Why?
| | Emigrants and Immigrants | 1 | 2014 | 25 | 0.140 |
Why?
| | Cost Savings | 1 | 2014 | 38 | 0.140 |
Why?
| | Ventilator Weaning | 1 | 2015 | 33 | 0.140 |
Why?
| | Genetic Markers | 1 | 2014 | 51 | 0.140 |
Why?
| | Severity of Illness Index | 8 | 2008 | 1240 | 0.140 |
Why?
| | Membrane Transport Proteins | 1 | 2014 | 51 | 0.140 |
Why?
| | Breast Diseases | 1 | 1993 | 6 | 0.130 |
Why?
| | Outpatient Clinics, Hospital | 2 | 2004 | 14 | 0.130 |
Why?
| | Inpatients | 2 | 2009 | 154 | 0.130 |
Why?
| | Surgical Procedures, Operative | 4 | 2013 | 40 | 0.130 |
Why?
| | Soaps | 4 | 2010 | 9 | 0.130 |
Why?
| | Blood | 2 | 2010 | 30 | 0.130 |
Why?
| | Drug Prescriptions | 3 | 2003 | 37 | 0.130 |
Why?
| | Abscess | 1 | 1993 | 23 | 0.130 |
Why?
| | Tooth Socket | 1 | 2013 | 1 | 0.130 |
Why?
| | Thailand | 1 | 2013 | 14 | 0.130 |
Why?
| | Odds Ratio | 4 | 2021 | 327 | 0.130 |
Why?
| | Drug Resistance | 2 | 2003 | 68 | 0.130 |
Why?
| | Models, Statistical | 4 | 2016 | 144 | 0.130 |
Why?
| | Hospital Departments | 2 | 2002 | 9 | 0.130 |
Why?
| | Longitudinal Studies | 5 | 2022 | 1452 | 0.120 |
Why?
| | Heart Failure | 1 | 2016 | 232 | 0.120 |
Why?
| | Multicenter Studies as Topic | 3 | 2001 | 73 | 0.120 |
Why?
| | Europe | 3 | 2014 | 88 | 0.120 |
Why?
| | Coronary Artery Bypass | 2 | 2011 | 75 | 0.120 |
Why?
| | Burnout, Professional | 1 | 2012 | 41 | 0.120 |
Why?
| | Multilocus Sequence Typing | 3 | 2021 | 12 | 0.120 |
Why?
| | Anti-HIV Agents | 2 | 2006 | 166 | 0.120 |
Why?
| | Epidemiologic Methods | 1 | 2012 | 22 | 0.120 |
Why?
| | Aspergillus niger | 1 | 1991 | 1 | 0.120 |
Why?
| | Charcoal | 1 | 1991 | 2 | 0.120 |
Why?
| | Paecilomyces | 1 | 1991 | 3 | 0.120 |
Why?
| | Penicillium | 1 | 1991 | 3 | 0.120 |
Why?
| | Pneumonia, Aspiration | 1 | 1991 | 9 | 0.120 |
Why?
| | Lung Diseases, Fungal | 1 | 1991 | 10 | 0.120 |
Why?
| | Aspergillosis | 1 | 1991 | 14 | 0.120 |
Why?
| | Emotions | 1 | 2012 | 98 | 0.120 |
Why?
| | Brucella | 1 | 2011 | 2 | 0.120 |
Why?
| | Brucellosis | 1 | 2011 | 3 | 0.120 |
Why?
| | Osteomyelitis | 2 | 2005 | 23 | 0.120 |
Why?
| | HIV | 1 | 2012 | 89 | 0.110 |
Why?
| | Quality Assurance, Health Care | 2 | 2010 | 54 | 0.110 |
Why?
| | Serratia marcescens | 2 | 2010 | 11 | 0.110 |
Why?
| | Guided Tissue Regeneration, Periodontal | 1 | 2010 | 1 | 0.110 |
Why?
| | Peritoneal Diseases | 1 | 2010 | 4 | 0.110 |
Why?
| | Patient Readmission | 1 | 2012 | 129 | 0.110 |
Why?
| | Models, Biological | 1 | 2014 | 428 | 0.110 |
Why?
| | Medical Office Buildings | 1 | 2010 | 1 | 0.110 |
Why?
| | Oropharynx | 1 | 1990 | 2 | 0.110 |
Why?
| | Gastrointestinal Diseases | 1 | 1991 | 42 | 0.110 |
Why?
| | Comorbidity | 3 | 2019 | 562 | 0.110 |
Why?
| | beta-Lactams | 3 | 2007 | 10 | 0.110 |
Why?
| | Efficiency | 1 | 2010 | 21 | 0.110 |
Why?
| | Blood Platelets | 1 | 2010 | 52 | 0.110 |
Why?
| | Cephalosporin Resistance | 2 | 2001 | 2 | 0.110 |
Why?
| | Pancreatitis, Acute Necrotizing | 2 | 2001 | 4 | 0.110 |
Why?
| | Medicare | 1 | 2011 | 113 | 0.110 |
Why?
| | Serratia | 3 | 2010 | 7 | 0.110 |
Why?
| | Ecosystem | 2 | 2021 | 25 | 0.110 |
Why?
| | Kidney Diseases | 1 | 2012 | 146 | 0.100 |
Why?
| | Knowledge Bases | 1 | 2010 | 3 | 0.100 |
Why?
| | Azlocillin | 1 | 1989 | 1 | 0.100 |
Why?
| | Hospitals, Special | 1 | 2009 | 6 | 0.100 |
Why?
| | Organizational Policy | 1 | 2009 | 16 | 0.100 |
Why?
| | Linear Models | 1 | 2010 | 276 | 0.100 |
Why?
| | Substance-Related Disorders | 4 | 2015 | 115 | 0.100 |
Why?
| | Patient Care Planning | 2 | 1995 | 58 | 0.100 |
Why?
| | Fever | 1 | 1989 | 38 | 0.100 |
Why?
| | Ventilators, Negative-Pressure | 1 | 2009 | 1 | 0.100 |
Why?
| | Urinary Catheterization | 2 | 2008 | 6 | 0.100 |
Why?
| | Patient Admission | 2 | 2002 | 34 | 0.100 |
Why?
| | Administration, Intranasal | 2 | 2019 | 25 | 0.100 |
Why?
| | Drug Administration Schedule | 2 | 2008 | 257 | 0.100 |
Why?
| | Follow-Up Studies | 4 | 2019 | 2028 | 0.090 |
Why?
| | Sputum | 3 | 2015 | 23 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2010 | 82 | 0.090 |
Why?
| | False Positive Reactions | 3 | 1998 | 40 | 0.090 |
Why?
| | Healthcare Disparities | 1 | 2010 | 82 | 0.090 |
Why?
| | Cefotaxime | 2 | 1986 | 5 | 0.090 |
Why?
| | Predictive Value of Tests | 2 | 2010 | 637 | 0.090 |
Why?
| | Pancreatitis | 2 | 2000 | 29 | 0.090 |
Why?
| | Foodborne Diseases | 1 | 2008 | 3 | 0.090 |
Why?
| | Molecular Sequence Data | 2 | 2014 | 315 | 0.090 |
Why?
| | Lactams | 2 | 2005 | 6 | 0.090 |
Why?
| | Los Angeles | 5 | 2000 | 10 | 0.090 |
Why?
| | Antisepsis | 3 | 2003 | 3 | 0.090 |
Why?
| | Bedding and Linens | 1 | 2007 | 5 | 0.090 |
Why?
| | Folliculitis | 1 | 1987 | 1 | 0.090 |
Why?
| | Porifera | 1 | 1987 | 1 | 0.090 |
Why?
| | Health Facilities | 1 | 2007 | 11 | 0.090 |
Why?
| | Statistics, Nonparametric | 2 | 2004 | 156 | 0.090 |
Why?
| | Random Allocation | 4 | 2000 | 164 | 0.090 |
Why?
| | Renal Dialysis | 2 | 2015 | 117 | 0.090 |
Why?
| | Cost Control | 1 | 2006 | 11 | 0.080 |
Why?
| | Software | 2 | 2006 | 74 | 0.080 |
Why?
| | Inservice Training | 1 | 2006 | 30 | 0.080 |
Why?
| | Carbon | 1 | 2006 | 8 | 0.080 |
Why?
| | Platinum | 1 | 2006 | 6 | 0.080 |
Why?
| | Neoplasms | 1 | 1989 | 280 | 0.080 |
Why?
| | Aging | 1 | 1996 | 1614 | 0.080 |
Why?
| | Contact Tracing | 2 | 2011 | 6 | 0.080 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2005 | 5 | 0.080 |
Why?
| | Fellowships and Scholarships | 1 | 2006 | 38 | 0.080 |
Why?
| | Aminoglycosides | 6 | 1987 | 11 | 0.080 |
Why?
| | Bronchoscopy | 4 | 2003 | 38 | 0.080 |
Why?
| | Sex Factors | 3 | 2015 | 542 | 0.070 |
Why?
| | AIDS Serodiagnosis | 1 | 2005 | 6 | 0.070 |
Why?
| | Quality of Life | 1 | 2010 | 663 | 0.070 |
Why?
| | Age Factors | 3 | 2004 | 943 | 0.070 |
Why?
| | Sexually Transmitted Diseases | 1 | 2005 | 16 | 0.070 |
Why?
| | Survival Rate | 3 | 2003 | 465 | 0.070 |
Why?
| | Dental Plaque Index | 1 | 2004 | 1 | 0.070 |
Why?
| | Tooth Discoloration | 1 | 2004 | 1 | 0.070 |
Why?
| | Dental Implantation | 1 | 2004 | 2 | 0.070 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2004 | 20 | 0.070 |
Why?
| | Lumbosacral Region | 1 | 2005 | 71 | 0.070 |
Why?
| | Treatment Failure | 1 | 2005 | 187 | 0.070 |
Why?
| | Societies, Medical | 1 | 2006 | 209 | 0.070 |
Why?
| | Zoonoses | 1 | 2004 | 9 | 0.070 |
Why?
| | Health Planning | 1 | 2004 | 5 | 0.070 |
Why?
| | Severe Acute Respiratory Syndrome | 1 | 2004 | 3 | 0.070 |
Why?
| | Patient Participation | 1 | 2005 | 52 | 0.070 |
Why?
| | Recombinant Proteins | 3 | 2001 | 295 | 0.070 |
Why?
| | Sanitary Engineering | 1 | 1984 | 1 | 0.070 |
Why?
| | Transducers | 3 | 1986 | 10 | 0.070 |
Why?
| | Analysis of Variance | 3 | 2017 | 364 | 0.070 |
Why?
| | Sentinel Surveillance | 1 | 2003 | 8 | 0.070 |
Why?
| | Radiology Information Systems | 1 | 2003 | 3 | 0.070 |
Why?
| | Pancreatic Diseases | 1 | 1983 | 4 | 0.070 |
Why?
| | Research Design | 1 | 2006 | 238 | 0.070 |
Why?
| | History, 20th Century | 2 | 2013 | 94 | 0.070 |
Why?
| | Obstetrics and Gynecology Department, Hospital | 1 | 1983 | 4 | 0.070 |
Why?
| | Sarcoidosis | 1 | 1983 | 15 | 0.070 |
Why?
| | Database Management Systems | 1 | 2003 | 1 | 0.070 |
Why?
| | Computer Systems | 1 | 2003 | 6 | 0.070 |
Why?
| | Blood-Borne Pathogens | 1 | 2003 | 5 | 0.070 |
Why?
| | Monitoring, Physiologic | 3 | 1986 | 100 | 0.070 |
Why?
| | Computer Communication Networks | 1 | 2003 | 5 | 0.070 |
Why?
| | Patient Acceptance of Health Care | 1 | 2004 | 85 | 0.060 |
Why?
| | Infant, Newborn, Diseases | 1 | 1983 | 18 | 0.060 |
Why?
| | Facility Design and Construction | 1 | 2003 | 2 | 0.060 |
Why?
| | Hospitals, Community | 1 | 2003 | 21 | 0.060 |
Why?
| | Pregnancy Complications, Infectious | 1 | 1983 | 34 | 0.060 |
Why?
| | Models, Theoretical | 2 | 2021 | 112 | 0.060 |
Why?
| | Kidney Function Tests | 1 | 2002 | 29 | 0.060 |
Why?
| | Hospitals, Municipal | 1 | 2002 | 1 | 0.060 |
Why?
| | Pneumococcal Infections | 1 | 2002 | 9 | 0.060 |
Why?
| | Home Care Services | 1 | 2002 | 27 | 0.060 |
Why?
| | New York City | 2 | 2000 | 23 | 0.060 |
Why?
| | Deoxycholic Acid | 1 | 2002 | 3 | 0.060 |
Why?
| | Blood Pressure Determination | 2 | 1986 | 22 | 0.060 |
Why?
| | Therapies, Investigational | 1 | 2022 | 6 | 0.060 |
Why?
| | Sequence Analysis, RNA | 1 | 2002 | 43 | 0.060 |
Why?
| | Medication Errors | 1 | 2002 | 20 | 0.060 |
Why?
| | Patient Compliance | 1 | 2004 | 200 | 0.060 |
Why?
| | Animal Husbandry | 1 | 2001 | 6 | 0.060 |
Why?
| | Base Sequence | 1 | 2002 | 166 | 0.060 |
Why?
| | North America | 1 | 2001 | 44 | 0.060 |
Why?
| | Gift Giving | 1 | 2021 | 1 | 0.060 |
Why?
| | Hand Sanitizers | 1 | 2021 | 1 | 0.060 |
Why?
| | Social Determinants of Health | 1 | 2022 | 22 | 0.060 |
Why?
| | Methicillin | 1 | 2021 | 7 | 0.060 |
Why?
| | Polymerase Chain Reaction | 3 | 2016 | 188 | 0.060 |
Why?
| | Glucagon | 1 | 2001 | 6 | 0.060 |
Why?
| | Intestinal Mucosa | 2 | 2001 | 235 | 0.060 |
Why?
| | Employment | 1 | 2021 | 39 | 0.060 |
Why?
| | Drug Therapy, Computer-Assisted | 1 | 2001 | 6 | 0.060 |
Why?
| | Confidentiality | 1 | 2001 | 12 | 0.060 |
Why?
| | Health Surveys | 1 | 2021 | 102 | 0.060 |
Why?
| | Meningitis | 2 | 1984 | 10 | 0.060 |
Why?
| | Lung Diseases | 2 | 1998 | 54 | 0.050 |
Why?
| | Health Education | 1 | 2001 | 50 | 0.050 |
Why?
| | Geography | 2 | 2011 | 22 | 0.050 |
Why?
| | Anticoagulants | 1 | 2002 | 151 | 0.050 |
Why?
| | Waste Disposal, Fluid | 1 | 2020 | 3 | 0.050 |
Why?
| | Peptides | 1 | 2001 | 116 | 0.050 |
Why?
| | Escherichia coli Proteins | 1 | 2020 | 14 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2001 | 230 | 0.050 |
Why?
| | California | 1 | 2019 | 35 | 0.050 |
Why?
| | Respiratory Insufficiency | 1 | 2000 | 48 | 0.050 |
Why?
| | Platelet Activating Factor | 1 | 1999 | 8 | 0.050 |
Why?
| | Leucine | 1 | 1999 | 18 | 0.050 |
Why?
| | Interleukin-6 | 1 | 2000 | 120 | 0.050 |
Why?
| | Lumbar Vertebrae | 1 | 2005 | 469 | 0.050 |
Why?
| | Computer Simulation | 1 | 2021 | 249 | 0.050 |
Why?
| | Enteral Nutrition | 2 | 1998 | 64 | 0.050 |
Why?
| | Homes for the Aged | 1 | 1999 | 9 | 0.050 |
Why?
| | Haemophilus influenzae | 1 | 1999 | 1 | 0.050 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1998 | 7 | 0.050 |
Why?
| | Biopsy | 2 | 2017 | 283 | 0.050 |
Why?
| | Ear, Middle | 1 | 1999 | 7 | 0.050 |
Why?
| | Leukemia, Hairy Cell | 1 | 1978 | 2 | 0.050 |
Why?
| | Academic Medical Centers | 2 | 2010 | 158 | 0.050 |
Why?
| | ROC Curve | 1 | 2019 | 153 | 0.050 |
Why?
| | Imidazoles | 1 | 1999 | 74 | 0.050 |
Why?
| | Statistics as Topic | 1 | 1998 | 124 | 0.050 |
Why?
| | Homosexuality | 2 | 1995 | 9 | 0.050 |
Why?
| | Societies, Scientific | 1 | 1998 | 12 | 0.050 |
Why?
| | Patient Care Management | 1 | 1998 | 18 | 0.040 |
Why?
| | Gram-Positive Cocci | 2 | 2008 | 5 | 0.040 |
Why?
| | Hemodynamics | 1 | 1998 | 103 | 0.040 |
Why?
| | Hepatitis B | 2 | 1981 | 19 | 0.040 |
Why?
| | Nebulizers and Vaporizers | 1 | 1998 | 21 | 0.040 |
Why?
| | Dental Prosthesis Design | 1 | 2017 | 1 | 0.040 |
Why?
| | Acid Etching, Dental | 1 | 2017 | 2 | 0.040 |
Why?
| | Dental Alloys | 1 | 2017 | 4 | 0.040 |
Why?
| | Virus Diseases | 1 | 1997 | 15 | 0.040 |
Why?
| | Freezing | 1 | 1997 | 14 | 0.040 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2017 | 81 | 0.040 |
Why?
| | Mycoses | 1 | 1997 | 23 | 0.040 |
Why?
| | Agranulocytosis | 2 | 1989 | 7 | 0.040 |
Why?
| | Implants, Experimental | 1 | 2017 | 29 | 0.040 |
Why?
| | Evidence-Based Practice | 1 | 2018 | 86 | 0.040 |
Why?
| | Temperature | 1 | 2017 | 85 | 0.040 |
Why?
| | Patient Education as Topic | 1 | 2019 | 192 | 0.040 |
Why?
| | Epidermal Growth Factor | 1 | 1997 | 33 | 0.040 |
Why?
| | Swine | 1 | 2017 | 117 | 0.040 |
Why?
| | Research Personnel | 1 | 2017 | 22 | 0.040 |
Why?
| | Surface Properties | 1 | 2017 | 139 | 0.040 |
Why?
| | Hospital Bed Capacity | 1 | 1996 | 7 | 0.040 |
Why?
| | Models, Animal | 1 | 2017 | 149 | 0.040 |
Why?
| | Confidence Intervals | 2 | 2012 | 102 | 0.040 |
Why?
| | Product Surveillance, Postmarketing | 1 | 1996 | 19 | 0.040 |
Why?
| | Selection, Genetic | 1 | 2016 | 6 | 0.040 |
Why?
| | Genes, Bacterial | 1 | 2016 | 8 | 0.040 |
Why?
| | Resuscitation Orders | 1 | 1996 | 5 | 0.040 |
Why?
| | Hospitals, Veterans | 1 | 1996 | 6 | 0.040 |
Why?
| | Teicoplanin | 1 | 1996 | 5 | 0.040 |
Why?
| | Ampicillin | 1 | 1996 | 8 | 0.040 |
Why?
| | Gastrointestinal Tract | 1 | 2017 | 52 | 0.040 |
Why?
| | Materials Testing | 1 | 2017 | 140 | 0.040 |
Why?
| | Sex Distribution | 1 | 1996 | 89 | 0.040 |
Why?
| | Sternum | 1 | 1976 | 5 | 0.040 |
Why?
| | Age Distribution | 1 | 1996 | 110 | 0.040 |
Why?
| | Mediastinitis | 1 | 1976 | 7 | 0.040 |
Why?
| | Ceramics | 1 | 2016 | 22 | 0.040 |
Why?
| | Bacterial Adhesion | 1 | 1996 | 6 | 0.040 |
Why?
| | Wounds and Injuries | 1 | 1996 | 58 | 0.040 |
Why?
| | Histoplasma | 1 | 1995 | 3 | 0.040 |
Why?
| | Bone Substitutes | 1 | 2016 | 34 | 0.040 |
Why?
| | Insurance, Hospitalization | 1 | 1995 | 2 | 0.040 |
Why?
| | Mucous Membrane | 1 | 1996 | 42 | 0.040 |
Why?
| | Candida | 1 | 2015 | 18 | 0.040 |
Why?
| | Guatemala | 1 | 1995 | 1 | 0.040 |
Why?
| | Cattle | 1 | 2016 | 260 | 0.040 |
Why?
| | Diffusion | 2 | 2014 | 28 | 0.040 |
Why?
| | Leadership | 1 | 2017 | 109 | 0.040 |
Why?
| | Staining and Labeling | 1 | 1975 | 27 | 0.040 |
Why?
| | CD4 Lymphocyte Count | 1 | 1996 | 161 | 0.040 |
Why?
| | Bisexuality | 1 | 1995 | 9 | 0.040 |
Why?
| | Florida | 4 | 1995 | 17 | 0.040 |
Why?
| | Markov Chains | 1 | 2015 | 32 | 0.040 |
Why?
| | Urban Health Services | 1 | 2015 | 18 | 0.040 |
Why?
| | Cerebrospinal Fluid | 1 | 1975 | 22 | 0.040 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2015 | 14 | 0.040 |
Why?
| | Osteogenesis | 1 | 2016 | 94 | 0.040 |
Why?
| | Cytokines | 1 | 1998 | 364 | 0.040 |
Why?
| | Coagulase | 2 | 1993 | 2 | 0.040 |
Why?
| | Biocompatible Materials | 1 | 2016 | 112 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2015 | 56 | 0.040 |
Why?
| | Pulmonary Atelectasis | 1 | 2015 | 4 | 0.040 |
Why?
| | Gastric Juice | 1 | 2015 | 3 | 0.040 |
Why?
| | Drinking Water | 1 | 2015 | 4 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2015 | 19 | 0.040 |
Why?
| | Pentazocine | 2 | 1985 | 2 | 0.040 |
Why?
| | Tripelennamine | 2 | 1985 | 2 | 0.040 |
Why?
| | Pulmonary Edema | 1 | 2015 | 14 | 0.040 |
Why?
| | Syria | 1 | 2014 | 1 | 0.040 |
Why?
| | Management Audit | 1 | 2014 | 2 | 0.040 |
Why?
| | Epidemiological Monitoring | 1 | 2014 | 8 | 0.040 |
Why?
| | Virulence Factors | 1 | 2014 | 10 | 0.040 |
Why?
| | Forecasting | 1 | 1995 | 134 | 0.040 |
Why?
| | Delirium | 1 | 2015 | 41 | 0.040 |
Why?
| | Hand Hygiene | 1 | 2014 | 2 | 0.040 |
Why?
| | Minority Groups | 1 | 1995 | 79 | 0.040 |
Why?
| | Tibia | 1 | 2017 | 266 | 0.040 |
Why?
| | Thromboembolism | 1 | 2015 | 37 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 1995 | 113 | 0.040 |
Why?
| | United States Occupational Safety and Health Administration | 1 | 1994 | 1 | 0.030 |
Why?
| | Organizational Culture | 1 | 2014 | 22 | 0.030 |
Why?
| | Planning Techniques | 1 | 1994 | 15 | 0.030 |
Why?
| | Campylobacter Infections | 1 | 2014 | 11 | 0.030 |
Why?
| | Acute Disease | 3 | 2000 | 254 | 0.030 |
Why?
| | Nafcillin | 1 | 1993 | 1 | 0.030 |
Why?
| | Clindamycin | 1 | 1993 | 3 | 0.030 |
Why?
| | Focus Groups | 1 | 2014 | 93 | 0.030 |
Why?
| | Longevity | 1 | 2014 | 35 | 0.030 |
Why?
| | History, 21st Century | 1 | 2013 | 39 | 0.030 |
Why?
| | Chickens | 1 | 2014 | 56 | 0.030 |
Why?
| | Drug Discovery | 1 | 2013 | 24 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 3 | 2001 | 494 | 0.030 |
Why?
| | Publishing | 1 | 1994 | 37 | 0.030 |
Why?
| | Qualitative Research | 1 | 2014 | 127 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2013 | 9 | 0.030 |
Why?
| | Double-Blind Method | 1 | 1995 | 559 | 0.030 |
Why?
| | Alveolar Process | 1 | 2013 | 1 | 0.030 |
Why?
| | Alveolar Ridge Augmentation | 1 | 2013 | 1 | 0.030 |
Why?
| | Periodontium | 1 | 2013 | 1 | 0.030 |
Why?
| | Drainage | 1 | 1993 | 55 | 0.030 |
Why?
| | Esthetics, Dental | 1 | 2013 | 2 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 1993 | 117 | 0.030 |
Why?
| | Indiana | 2 | 2011 | 18 | 0.030 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 221 | 0.030 |
Why?
| | Surgical Flaps | 1 | 2013 | 54 | 0.030 |
Why?
| | Propensity Score | 1 | 2012 | 54 | 0.030 |
Why?
| | Rats | 3 | 2001 | 966 | 0.030 |
Why?
| | HIV Core Protein p24 | 1 | 1992 | 29 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 1992 | 91 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 230 | 0.030 |
Why?
| | Lung Diseases, Obstructive | 1 | 1991 | 6 | 0.030 |
Why?
| | Splenomegaly | 1 | 2011 | 5 | 0.030 |
Why?
| | Virulence | 1 | 2011 | 13 | 0.030 |
Why?
| | Milk | 1 | 2011 | 10 | 0.030 |
Why?
| | Gastric Acidity Determination | 1 | 1991 | 2 | 0.030 |
Why?
| | Insurance Claim Reporting | 1 | 2011 | 1 | 0.030 |
Why?
| | Mexico | 1 | 2011 | 18 | 0.030 |
Why?
| | Hepatomegaly | 1 | 2011 | 6 | 0.030 |
Why?
| | Pneumonia, Staphylococcal | 1 | 2011 | 9 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2013 | 227 | 0.030 |
Why?
| | Administration, Topical | 1 | 1991 | 24 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 1991 | 55 | 0.030 |
Why?
| | Prednisone | 1 | 1991 | 75 | 0.030 |
Why?
| | Comparative Genomic Hybridization | 1 | 2011 | 4 | 0.030 |
Why?
| | Clone Cells | 1 | 2011 | 21 | 0.030 |
Why?
| | Gene Frequency | 1 | 2011 | 80 | 0.030 |
Why?
| | Syringes | 1 | 2010 | 12 | 0.030 |
Why?
| | Pulmonary Embolism | 1 | 2011 | 57 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2010 | 52 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2010 | 132 | 0.030 |
Why?
| | Bone Transplantation | 1 | 2013 | 231 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 1993 | 224 | 0.030 |
Why?
| | Recurrence | 1 | 2011 | 389 | 0.030 |
Why?
| | Automation | 1 | 2010 | 12 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2010 | 152 | 0.030 |
Why?
| | Decision Support Systems, Clinical | 1 | 2010 | 12 | 0.030 |
Why?
| | Adenocarcinoma | 1 | 1991 | 237 | 0.030 |
Why?
| | Ileum | 2 | 2001 | 31 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 1991 | 378 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2010 | 100 | 0.020 |
Why?
| | Escherichia coli O157 | 1 | 2008 | 2 | 0.020 |
Why?
| | Salmonella | 1 | 2008 | 5 | 0.020 |
Why?
| | Mutation | 3 | 1986 | 464 | 0.020 |
Why?
| | Citrobacter | 1 | 1987 | 1 | 0.020 |
Why?
| | Oxacillin | 1 | 1987 | 3 | 0.020 |
Why?
| | Lymph Nodes | 2 | 1999 | 84 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2006 | 12 | 0.020 |
Why?
| | Allied Health Personnel | 1 | 2006 | 12 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2006 | 55 | 0.020 |
Why?
| | Transducers, Pressure | 1 | 1986 | 5 | 0.020 |
Why?
| | Environmental Monitoring | 1 | 2006 | 8 | 0.020 |
Why?
| | Diphtheria | 1 | 1985 | 1 | 0.020 |
Why?
| | Georgia | 2 | 1976 | 16 | 0.020 |
Why?
| | Nurses | 1 | 2006 | 51 | 0.020 |
Why?
| | Patients | 1 | 2006 | 26 | 0.020 |
Why?
| | Penicillanic Acid | 1 | 2005 | 3 | 0.020 |
Why?
| | Piperacillin | 1 | 2005 | 3 | 0.020 |
Why?
| | Metronidazole | 1 | 2005 | 9 | 0.020 |
Why?
| | Ceftriaxone | 1 | 2005 | 6 | 0.020 |
Why?
| | Deltaretrovirus | 1 | 1985 | 1 | 0.020 |
Why?
| | Blood Donors | 1 | 1985 | 7 | 0.020 |
Why?
| | Serotyping | 4 | 1987 | 12 | 0.020 |
Why?
| | Digestive System Surgical Procedures | 1 | 2005 | 27 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 1991 | 756 | 0.020 |
Why?
| | Infant, Premature | 1 | 1986 | 226 | 0.020 |
Why?
| | Health Planning Guidelines | 1 | 2004 | 11 | 0.020 |
Why?
| | Ibuprofen | 1 | 1984 | 12 | 0.020 |
Why?
| | Moxalactam | 1 | 1983 | 1 | 0.020 |
Why?
| | Cefoxitin | 1 | 1983 | 2 | 0.020 |
Why?
| | Echinococcosis, Hepatic | 1 | 1983 | 1 | 0.020 |
Why?
| | Echinococcosis, Pulmonary | 1 | 1983 | 1 | 0.020 |
Why?
| | Mebendazole | 1 | 1983 | 1 | 0.020 |
Why?
| | Nurseries, Hospital | 1 | 1983 | 5 | 0.020 |
Why?
| | Maternal-Fetal Exchange | 1 | 1983 | 11 | 0.020 |
Why?
| | Policy Making | 1 | 1983 | 16 | 0.020 |
Why?
| | Eosinophilia | 1 | 1984 | 49 | 0.020 |
Why?
| | Milk, Human | 1 | 1986 | 186 | 0.020 |
Why?
| | Resource Allocation | 1 | 2003 | 5 | 0.020 |
Why?
| | Benzimidazoles | 1 | 1983 | 15 | 0.020 |
Why?
| | Blood Pressure Monitors | 1 | 2002 | 1 | 0.020 |
Why?
| | Umbilical Arteries | 1 | 2002 | 4 | 0.020 |
Why?
| | R Factors | 1 | 1982 | 2 | 0.020 |
Why?
| | Disease Reservoirs | 1 | 2002 | 10 | 0.010 |
Why?
| | Patient Selection | 1 | 2004 | 264 | 0.010 |
Why?
| | Plasmodium falciparum | 1 | 1981 | 4 | 0.010 |
Why?
| | Malaria | 1 | 1981 | 6 | 0.010 |
Why?
| | Glucagon-Like Peptides | 1 | 2001 | 2 | 0.010 |
Why?
| | Glucagon-Like Peptide 2 | 1 | 2001 | 2 | 0.010 |
Why?
| | Jejunum | 1 | 2001 | 14 | 0.010 |
Why?
| | Permeability | 1 | 2001 | 143 | 0.010 |
Why?
| | Conjugation, Genetic | 2 | 1996 | 5 | 0.010 |
Why?
| | Breast Feeding | 1 | 1983 | 177 | 0.010 |
Why?
| | Netilmicin | 1 | 1980 | 1 | 0.010 |
Why?
| | Pseudomonadaceae | 1 | 1980 | 1 | 0.010 |
Why?
| | Blood Cell Count | 1 | 2000 | 19 | 0.010 |
Why?
| | Cecum | 1 | 2000 | 10 | 0.010 |
Why?
| | Weight Loss | 1 | 2001 | 114 | 0.010 |
Why?
| | Urine | 1 | 1980 | 10 | 0.010 |
Why?
| | Pancreas | 1 | 2000 | 36 | 0.010 |
Why?
| | Amylases | 1 | 1999 | 6 | 0.010 |
Why?
| | Dogs | 1 | 2000 | 283 | 0.010 |
Why?
| | Rheumatic Fever | 1 | 1979 | 2 | 0.010 |
Why?
| | C-Reactive Protein | 1 | 2000 | 134 | 0.010 |
Why?
| | Gonorrhea | 1 | 1979 | 8 | 0.010 |
Why?
| | Carbon-Oxygen Ligases | 1 | 1999 | 2 | 0.010 |
Why?
| | Haemophilus Infections | 1 | 1999 | 2 | 0.010 |
Why?
| | Leukemia, Lymphoid | 1 | 1978 | 2 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1999 | 230 | 0.010 |
Why?
| | Gastroenteritis | 1 | 1977 | 4 | 0.010 |
Why?
| | Cefazolin | 2 | 1988 | 6 | 0.010 |
Why?
| | Hepatitis | 1 | 1977 | 9 | 0.010 |
Why?
| | Skin Diseases, Infectious | 1 | 1977 | 9 | 0.010 |
Why?
| | Diagnostic Errors | 1 | 1977 | 48 | 0.010 |
Why?
| | Mesentery | 1 | 1997 | 6 | 0.010 |
Why?
| | Serum Albumin, Bovine | 1 | 1997 | 9 | 0.010 |
Why?
| | Laparotomy | 1 | 1997 | 25 | 0.010 |
Why?
| | Postoperative Complications | 1 | 1985 | 1083 | 0.010 |
Why?
| | Sterilization | 1 | 1976 | 10 | 0.010 |
Why?
| | Proteins | 1 | 1997 | 94 | 0.010 |
Why?
| | Pseudomonas | 1 | 1976 | 2 | 0.010 |
Why?
| | Saphenous Vein | 1 | 1976 | 16 | 0.010 |
Why?
| | Sexual Behavior | 1 | 1996 | 71 | 0.010 |
Why?
| | False Negative Reactions | 1 | 1975 | 16 | 0.010 |
Why?
| | North Carolina | 1 | 1995 | 12 | 0.010 |
Why?
| | Culture Techniques | 1 | 1975 | 38 | 0.010 |
Why?
| | Transplantation, Autologous | 1 | 1976 | 223 | 0.010 |
Why?
| | Laboratories | 1 | 1975 | 28 | 0.010 |
Why?
| | Leukocytes | 1 | 1975 | 50 | 0.010 |
Why?
| | Veterans | 1 | 1995 | 81 | 0.010 |
Why?
| | Isoelectric Focusing | 1 | 1993 | 7 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1993 | 47 | 0.010 |
Why?
| | Liver | 1 | 1975 | 214 | 0.010 |
Why?
| | Kinetics | 1 | 1993 | 278 | 0.010 |
Why?
| | AIDS-Related Complex | 1 | 1992 | 4 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 1992 | 41 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1992 | 96 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 1992 | 109 | 0.010 |
Why?
| | DNA, Viral | 1 | 1992 | 107 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1992 | 225 | 0.010 |
Why?
| | Peritoneum | 1 | 1986 | 19 | 0.010 |
Why?
| | Disposable Equipment | 1 | 1986 | 2 | 0.000 |
Why?
| | Diphtheria Toxoid | 1 | 1985 | 1 | 0.000 |
Why?
| | Immunization, Secondary | 1 | 1985 | 6 | 0.000 |
Why?
| | Immunization | 1 | 1985 | 50 | 0.000 |
Why?
| | Seasons | 1 | 1985 | 36 | 0.000 |
Why?
| | Viremia | 1 | 1985 | 36 | 0.000 |
Why?
| | HIV Antibodies | 1 | 1985 | 39 | 0.000 |
Why?
| | Drug Interactions | 1 | 1985 | 70 | 0.000 |
Why?
| | Antibodies, Viral | 1 | 1985 | 79 | 0.000 |
Why?
| | Cardiac Catheterization | 1 | 1986 | 110 | 0.000 |
Why?
| | Injections, Intravenous | 1 | 1984 | 61 | 0.000 |
Why?
| | Cefamandole | 1 | 1983 | 1 | 0.000 |
Why?
| | Hydrolysis | 1 | 1983 | 16 | 0.000 |
Why?
| | Bone Marrow | 1 | 1983 | 68 | 0.000 |
Why?
| | Africa, Eastern | 1 | 1981 | 1 | 0.000 |
Why?
| | Proteus Infections | 1 | 1976 | 1 | 0.000 |
Why?
|
|
Weinstein's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|